Evidence map›Paper›PMID 30202050›Full record

ArticleNature cell biology2018

A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma.

J Matthew Barnes, Shelly Kaushik, Russell O Bainer, Jason K Sa, Elliot C Woods, FuiBoon Kai, Laralynne Przybyla, Mijeong Lee, Hye Won Lee, Jason C Tung and 12 more

Open access · greenAbstract read
In one paragraph

Article in Nature cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 1 synthesis or guideline pooled it, 174 citations in OpenAlex.

  1. Physical Forces in Glioblastoma Migration: A Systematic Review.International journal of molecular sciences · 2022
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. MUC15 Ectodomain Architecture Regulates Integrin Clustering to Control Cancer Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  14. Article
  15. Membrane-Inserting α‑Lipid Polymers: Understanding Lipid Membrane Insertion and Effect on Membrane Fluidity.Chemistry of materials : a publication of the American Chemical Society · 2025
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 3 countries.

J Matthew BarnesCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Shelly KaushikCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Russell O BainerCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Jason K SaInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Elliot C WoodsDepartment of Chemistry and Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.
FuiBoon KaiCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Laralynne PrzybylaCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Mijeong LeeInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Hye Won LeeInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Jason C TungCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Ori MallerCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Alexander S BarrettDepartment of Biochemistry and Molecular Genetics, University of Colorado, Denver, Aurora, CO, USA.
Kan V LuUCSF Department of Neurological Surgery, Helen Diller Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Jonathon N LakinsCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Kirk C HansenDepartment of Biochemistry and Molecular Genetics, University of Colorado, Denver, Aurora, CO, USA.
Kirsten ObernierUCSF Department of Neurological Surgery, Helen Diller Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Arturo Alvarez-BuyllaUCSF Department of Neurological Surgery, Helen Diller Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Gabriele BergersUCSF Department of Neurological Surgery, Helen Diller Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Joanna J PhillipsUCSF Department of Neurological Surgery, Helen Diller Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3789-8120
Do-Hyun NamInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Carolyn R BertozziDepartment of Chemistry and Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.
Valerie M WeaverCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA, USA. valerie.weaver@ucsf.edu.ORCID http://orcid.org/0000-0003-4786-6752
University of California, San Francisco · USSamsung Medical Center · KRHoward Hughes Medical Institute · USUniversity of Colorado Denver · US

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4M
Molecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4M
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Investigations of Golgi EnzymesR01GM059907 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI BERTOZZI, CAROLYN · 1999 to 2016
$5.9M
Training in Developmental Cardiovascular BiologyT32HL007544 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SRIVASTAVA, DEEPAK · 1985 to 2021
$4.5M
The vascular niche in glioma propagation and resistance to therapyU54CA163155 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAKINS, JOHNATHON NEIL · 2011 to 2015
$4.4M
Targeting the Cancer GlycocalyxR01CA227942 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2019 to 2026
$3.6M
ECM geometrical and mechanical properties modulate RTK signalingU01CA202241 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI GROVES, JAY T., WEAVER, VALERIE MARIE · 2015 to 2019
$3.3M
A biophysical stromal basis for radiation sensitivity in ductal carcinoma in situR01CA174929 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PARK, CATHERINE C, WEAVER, VALERIE MARIE · 2014 to 2018
$3.1M
Tension-Stat3-miR-mediated metastasisR01CA192914 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEEWALDT, VICTORIA L., WEAVER, VALERIE MARIE · 2015 to 2019
$2.9M
Extracellular Sulfatases As Novel Biomarkers For Early Detection of CancerU01CA168878 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEMJABBAR-ALAOUI, HASSAN, PHILLIPS, JOANNA · 2012 to 2016
$2.2M
Collagen remodeling and tumor progressionR01CA138818 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEAVER, VALERIE MARIE · 2010 to 2014
$2.0M
Howard Hughes Medical InstituteNCI NIH HHS F32 CA174319NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA138818NCI NIH HHS R01 CA174929NCI NIH HHS R01 CA192914NCI NIH HHS R01 CA227942NCI NIH HHS T32 CA108462NCI NIH HHS T32 CA151022NCI NIH HHS U01 CA168878NCI NIH HHS U01 CA202241NCI NIH HHS U54 CA163155NHLBI NIH HHS T32 HL007544NIGMS NIH HHS R01 GM059907NINDS NIH HHS R01 NS081117
6 · The paper itself

Abstract

Glioblastoma multiforme (GBMs) are recurrent lethal brain tumours. Recurrent GBMs often exhibit mesenchymal, stem-like phenotypes that could explain their resistance to therapy. Analyses revealed that recurrent GBMs have increased tension and express high levels of glycoproteins that increase the bulkiness of the glycocalyx. Studies showed that a bulky glycocalyx potentiates integrin mechanosignalling and tissue tension and promotes a mesenchymal, stem-like phenotype in GBMs. Gain- and loss-of-function studies implicated integrin mechanosignalling as an inducer of GBM growth, survival, invasion and treatment resistance, and a mesenchymal, stem-like phenotype. Mesenchymal-like GBMs were highly contractile and expressed elevated levels of glycoproteins that expanded their glycocalyx, and they were surrounded by a stiff extracellular matrix that potentiated integrin mechanosignalling. Our findings suggest that there is a dynamic and reciprocal link between integrin mechanosignalling and a bulky glycocalyx, implying a causal link towards a mesenchymal, stem-like phenotype in GBMs. Strategies to ameliorate GBM tissue tension offer a therapeutic approach to reduce mortality due to GBM.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingBrain NeoplasmsCell SurvivalFeedback, PhysiologicalGlioblastomaGlycocalyxHumansIntegrinsMesenchymal Stem CellsMice, NudeNeoplastic Stem CellsSurface TensionTemozolomideTumor Cells, CulturedXenograft Model Antitumor AssaysAntineoplastic Agents, AlkylatingIntegrinsTemozolomide

Identifiers

PMID30202050
PMCPMC6932748
OpenAlexW2890399078

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.